Syntrix Wins U.S. Patent 10,046,002 – Method for Treating Cancer Using Chemokine Antagonists

Syntrix Wins U.S. Patent 10,046,002 – Method for Treating Cancer Using Chemokine Antagonists
August 14, 2018 Syntrix

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean Y. (Seattle, WA); Schuler, Aaron D. (Auburn, WA) and Zebala, John A. (Sammamish, WA).

Representative Claim: A method for treating a patient with a cancer, comprising administering to the patient in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a compound having a structure selected from the group consisting of formulas SX-517, SX-576, and SX-682, or a pharmaceutically acceptable salt or solvate thereof, and performing at least one of (a), (b), (c) and (d), wherein (a) comprises assaying serum levels of CXCR1 and/or CXCR2 ligands in the patient prior to the treatment, (b) comprises assaying serum levels of CXCR1 and/or CXCR2 ligands in the patient after the treatment, (c) comprises assaying serum levels of myeloid derived suppressor cells (MDSCs) and/or neutrophils in the patient prior to the treatment, and (d) comprises assaying serum levels of MDSCs or neutrophils in the patient after the treatment.

Bitnami